Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487344 | 1.00 | DGAT1 (0.46) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL30511197 | 0.83 | TDP1 (0.37) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL20963156 | 0.80 | MEN1 (0.47) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL24191656 | 0.79 | DGAT1 (0.41) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL191649 | 0.79 | CA12 (0.41) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL1927273 | 0.78 | DGAT1 (0.41) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL29422137 | 0.77 | CA12 (0.41) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL28026126 | 0.77 | CA12 (0.41) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL14182678 | 0.77 | MEN1 (0.41) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL3685404 | 0.77 | MAOA (0.46) | DGAT1CA12CA14CA2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367332-B2 | Detection and quantification of abasic site formation in vivo | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100111861-A1 | DETECTION AND QUANTIFICATION OF ABASIC SITE FORMATION IN VIVO | CASE WESTERN RESERVE UNIVERSITY | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100111861-A1 | DETECTION AND QUANTIFICATION OF ABASIC SITE FORMATION IN VIVO | UNG, FEN1, DCLRE1B | DGAT1 3651/4885CA12 1916/4885CA14 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.